Amedisys Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Amedisys stock.
View analyst ratings for Amedisys or view top-rated stocks.

Wall Street analysts have given Amedisys a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amedisys wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Amedisys.

Amedisys, Inc. (NASDAQ:AMED) released its earnings results on Tuesday, February, 23rd. The health services provider reported $1.49 EPS for the quarter, topping analysts' consensus estimates of $1.47 by $0.02. Amedisys had a trailing twelve-month return on equity of 26.41% and a net margin of 8.22%. During the same period in the previous year, the company posted $0.94 earnings per share.
View Amedisys' earnings history.

Amedisys' stock was trading at $170.47 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AMED shares have increased by 43.4% and is now trading at $244.43.
View which stocks have been most impacted by COVID-19.

Amedisys updated its FY21 earnings guidance on Wednesday, February, 24th. The company provided EPS guidance of $6.25-6.47 for the period, compared to the Thomson Reuters consensus estimate of $6.33. The company issued revenue guidance of $2.275-2.315 billion, compared to the consensus revenue estimate of $2.31 billion.

12 brokers have issued 1 year price objectives for Amedisys' stock. Their forecasts range from $190.00 to $340.00. On average, they anticipate Amedisys' stock price to reach $274.46 in the next year. This suggests a possible upside of 12.3% from the stock's current price.
View analysts' price targets for Amedisys or view top-rated stocks among Wall Street analysts.

297 employees have rated Amedisys CEO Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among Amedisys' employees.

Some companies that are related to Amedisys include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Chemed (CHE), R1 RCM (RCM), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Biosciences (IDXG).
View all of AMED's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and The Home Depot (HD).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (12.13%), Price T Rowe Associates Inc. MD (4.76%), JPMorgan Chase & Co. (3.47%), William Blair Investment Management LLC (2.29%), Riverbridge Partners LLC (2.25%) and Wells Fargo & Company MN (1.96%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends for Amedisys.

AMED stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Ninety One UK Ltd, Squarepoint Ops LLC, Renaissance Technologies LLC, Pembroke Management LTD, and Victory Capital Management Inc.. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David L Kemmerly, Denise M Bohnert, Julie D Klapstein, Michael Paul North, Scott G Ginn, and Sharon Brunecz.
View insider buying and selling activity for Amedisys or view top insider-selling stocks.

AMED stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Thornburg Investment Management Inc., BlackRock Inc., JPMorgan Chase & Co., Alliancebernstein L.P., Price T Rowe Associates Inc. MD, Riverbridge Partners LLC, and AGF Investments Inc.. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps.
View insider buying and selling activity for Amedisys or or view top insider-buying stocks.

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMED stock can currently be purchased for approximately $244.43.

Amedisys has a market capitalization of $8.03 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis.

Amedisys employs 21,000 workers across the globe.

The official website for Amedisys is www.amedisys.com.

Amedisys is headquartered at 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]